6.27
price up icon3.64%   0.22
 
loading
전일 마감가:
$6.05
열려 있는:
$6.16
하루 거래량:
139.54K
Relative Volume:
0.13
시가총액:
$65.01M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.1194
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
-3.83%
1개월 성능:
-13.16%
6개월 성능:
+162.34%
1년 성능:
-63.38%
1일 변동 폭
Value
$6.0062
$6.56
1주일 범위
Value
$6.0062
$7.20
52주 변동 폭
Value
$1.80
$20.63

Cervomed Inc Stock (CRVO) Company Profile

Name
명칭
Cervomed Inc
Name
전화
(617) 744-4400
Name
주소
20 PARK PLAZA, BOSTON
Name
직원
15
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
CRVO's Discussions on Twitter

CRVO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CRVO
Cervomed Inc
6.27 65.01M 0 -6.42M -7.45M -5.6013
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.46 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.19 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.40 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.65 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.63 28.51B 3.81B -644.79M -669.77M -6.24

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-13 업그레이드 Chardan Capital Markets Neutral → Buy
2024-12-17 다운그레이드 H.C. Wainwright Buy → Neutral
2024-12-11 다운그레이드 Chardan Capital Markets Buy → Neutral
2024-12-11 다운그레이드 Morgan Stanley Overweight → Underweight
2024-12-10 다운그레이드 D. Boral Capital Buy → Hold
2024-12-06 개시 ROTH MKM Buy
2024-12-05 개시 H.C. Wainwright Buy
2024-09-18 개시 Chardan Capital Markets Buy
2024-07-26 개시 Morgan Stanley Overweight
2024-02-15 개시 Canaccord Genuity Buy
2020-11-17 다운그레이드 H.C. Wainwright Buy → Neutral
2018-03-21 개시 H.C. Wainwright Buy
모두보기

Cervomed Inc 주식(CRVO)의 최신 뉴스

pulisher
Jun 15, 2025

CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

CervoMed’s (CRVO) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Pric - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Price Held Steady | CRVO Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

CervoMed (CRVO) Strengthens Leadership with Key Executive Appoin - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

CervoMed (CRVO) Strengthens Leadership with Key Executive Appointment | CRVO Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

CervoMed appoints Marco Verwijs as EVP, technical operations - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - GlobeNewswire

Jun 10, 2025
pulisher
Jun 10, 2025

CervoMed Accelerates Phase 3 DLB Drug Development With Key Manufacturing Expert Hire - Stock Titan

Jun 10, 2025
pulisher
Jun 08, 2025

CRVOCervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - mx.advfn.com

Jun 08, 2025
pulisher
Jun 07, 2025

Nuveen Asset Management LLC Acquires 22,104 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Purchases New Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jun 05, 2025
pulisher
Jun 01, 2025

Reviewing CervoMed (CRVO) and Its Peers - Defense World

Jun 01, 2025
pulisher
May 21, 2025

CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World

May 21, 2025
pulisher
May 19, 2025

CervoMed Releases New Business and Financial Information - TipRanks

May 19, 2025
pulisher
May 19, 2025

Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews

May 19, 2025
pulisher
May 18, 2025

Chardan Capital Raises Earnings Estimates for CervoMed - Defense World

May 18, 2025
pulisher
May 16, 2025

Roth Capital Brokers Reduce Earnings Estimates for CervoMed - Defense World

May 16, 2025
pulisher
May 16, 2025

Brokers Set Expectations for CervoMed Q2 Earnings - Defense World

May 16, 2025
pulisher
May 15, 2025

Insider Buying: William Elder Acquires Additional Shares of Cerv - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from D. Boral Capital - Defense World

May 15, 2025
pulisher
May 15, 2025

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

CervoMed’s CFO Makes Bold Move with New Stock Purchase! - TipRanks

May 14, 2025
pulisher
May 14, 2025

CervoMed First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Chardan keeps CervoMed stock Buy rating, $15 target post-results - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Chardan Adjusts Price Target on CervoMed to $15 From $14, Maintains Buy Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | CRVO Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CervoMed Announces $50M Sales Agreement with Leerink - TipRanks

May 13, 2025
pulisher
May 13, 2025

Chardan Capital Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World

May 13, 2025
pulisher
May 13, 2025

CervoMed Inc. Reports Q1 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 12, 2025

Chardan keeps CervoMed stock Buy rating, $15 target post-results By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

CervoMed Inc (CRVO) Q1 2025 Earnings: Revenue Beats Estimates at $1.9M, Net Loss Reported - GuruFocus

May 12, 2025
pulisher
May 12, 2025

CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stoc - GuruFocus

May 12, 2025
pulisher
May 12, 2025

CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Cervomed Co Enters Sales Agreement With Leerink Partners LLC - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

CervoMed (CRVO) Financial Position and Funding Outlook | CRVO St - GuruFocus

May 12, 2025
pulisher
May 12, 2025

CervoMed (CRVO) Exceeds Q1 Revenue Expectations Amid Promising T - GuruFocus

May 12, 2025
pulisher
May 12, 2025

CervoMed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

SEC Form 10-Q filed by CervoMed Inc. - Quantisnow

May 12, 2025
pulisher
May 12, 2025

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

CervoMed Inc. Reports Positive Phase 2b Results for Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies and Plans Phase 3 Trial - Nasdaq

May 12, 2025
pulisher
May 12, 2025

CervoMed (CRVO) Financial Position and Funding Outlook | CRVO Stock News - GuruFocus

May 12, 2025
pulisher
May 11, 2025

CervoMed (CRVO) to Release Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 10, 2025

CervoMed Announces Executive Appointments and Changes - MSN

May 10, 2025
pulisher
May 10, 2025

Mariner LLC Invests $30,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World

May 10, 2025
pulisher
May 08, 2025

JPMorgan Chase & Co. Grows Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World

May 08, 2025
pulisher
May 07, 2025

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire

May 07, 2025
pulisher
May 02, 2025

CRVO Shares Experience Surge in Value - knoxdaily.com

May 02, 2025
pulisher
Apr 30, 2025

Head to Head Comparison: CervoMed (NASDAQ:CRVO) versus Schrödinger (NASDAQ:SDGR) - Defense World

Apr 30, 2025

Cervomed Inc (CRVO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Cervomed Inc 주식 (CRVO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
ELDER WILLIAM ROBERT
CFO & GC
Aug 27 '24
Buy
18.16
1,000
18,160
1,267
$20.55
price up icon 0.15%
$35.88
price up icon 0.07%
$20.95
price up icon 1.65%
$100.26
price up icon 0.88%
$106.34
price down icon 0.39%
biotechnology ONC
$240.60
price down icon 0.25%
자본화:     |  볼륨(24시간):